Posted by Michael Wonder on 02 Oct 2021
European Medicines Agency validates Bristol Myers Squibb’s application for LAG-3 blocking antibody relatlimab and nivolumab fixed dose combination as first-line treatment for patients with unresectable or metastatic melanoma
1 October 2021 - The Phase 2/3 RELATIVITY-047 trial served as the basis for this application, in which a statistically significant and clinically meaningful benefit was observed with relatlimab and nivolumab over Opdivo monotherapy.
Bristol Myers Squibb today announced that the EMA has validated its marketing authorisation application for the LAG-3-blocking antibody relatlimab and nivolumab fixed dose combination for first-line treatment of adult and paediatric patients (12 years and older and weighing at least 40 kg) with advanced (unresectable or metastatic) melanoma.
